Servier Advances OJEMDA Front-Line Brain Cancer Trial
BOSTON – May 8, 2026 Day One Biopharmaceuticals, now part of Servier Group, announced the completion of patient enrollment...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON – May 8, 2026 Day One Biopharmaceuticals, now part of Servier Group, announced the completion of patient enrollment...
Paris, France – April 22, 2026 In a major breakthrough for pediatric oncology, Ipsen has announced that the European...
